New research suggests that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Research printed in a leading medical journal shows that while overweight people frequently drop a large proportion of their total mass while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these drugs need to be aware of the danger of quick weight regain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
This pace of regain suggests a return to original weight in about 18 months.
Comparing Treatments
The research, which looked at dozens of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Researchers note that people who shed pounds through dieting typically have a more gradual creep back—around 100 grams monthly—post-intervention.
Understanding the Quick Regain
Nutrition scientists propose the mechanism of the jabs explains the amplified rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 levels several times higher than normal could lead to the body to produce less of its endogenous hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement means appetite is unsuppressed, making excessive eating far more likely."
A Lifelong Disease?
The NHS suggest the injections for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Professionals contend that, due to the high risk of relapse, the treatment should be considered ongoing.
This perspective is supported by pharmaceutical companies, who state that the findings "underscore the long-term character of obesity," similar to managing conditions like hypertension.
Patient Experiences
Users who have stopped the medication describe a sudden return of appetite.
"I experienced a trigger activating and I was suddenly ravenous," said one woman.
The struggle is exacerbated if patients have not adopted permanent dietary or behavioural modifications during therapy.
Significant Use
Figures show that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among women than men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, experts stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone solution and maintained weight loss relies on combined lifestyle management.
